CategorySurgical robots
Overview
Johnson and Johnson MedTech is the medical devices division of Johnson and Johnson, developing the Ottava robotic surgical system for soft-tissue surgery. Ottava received FDA De Novo authorization in 2026, positioning it as a competitor to Intuitive Surgical's da Vinci. Nearly six years from first unveiling to FDA clearance.
Verified record
- Verified deployments
- None on file
- Active incidents
- 2 incidents on file
Key facts
FDA clearance
Product
HQ
Parent
FDA
Competitor
Timeline
Data & sources
News coverage
1
1 source backing this record.View all →
Models (1)
View all models →Safety record
2 incidents on record (1 minor). Most recent: Jul 2026.
Most recent: Jul 2026
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Johnson and Johnson MedTech (2)
- FDA grants De Novo marketing authorization to J&J Ottava surgical robot2026-07-22 · Regulatory action
via Ottava
- FDA clears J&J Ottava surgical robot for US launch following de novo submission2026-07-22 · Regulatory action
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Johnson and Johnson MedTech in third-party press
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 23, 2026
Added to the verified registry
- Incident recordedJul 22, 2026
FDA grants De Novo marketing authorization to J&J Ottava surgical robot
- Incident recordedJul 22, 2026
FDA clears J&J Ottava surgical robot for US launch following de novo submission
Sources (1)
Common questions
- What is Johnson and Johnson MedTech?
- Johnson and Johnson MedTech is the medical devices division of Johnson and Johnson, developing the Ottava robotic surgical system for soft-tissue surgery. Ottava received FDA De Novo authorization in 2026, positioning it as a competitor to Intuitive Surgical's da Vinci. Nearly six years from first unveiling to FDA clearance.
- What does Johnson and Johnson MedTech make?
- Johnson and Johnson MedTech has 1 robot model on the DEPLOY registry: Ottava (Johnson and Johnson MedTech builds physical robots).
- Where is Johnson and Johnson MedTech headquartered?
- Johnson and Johnson MedTech is headquartered in New Brunswick, NJ, USA.
- Where does Johnson and Johnson MedTech operate robots?
- Johnson and Johnson MedTech is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- When was Johnson and Johnson MedTech founded?
- Johnson and Johnson MedTech was founded in 1886.
- Are there any incidents involving Johnson and Johnson MedTech?
- 2 active incidents involving Johnson and Johnson MedTech are on the DEPLOY registry. Each is a sourced, append-only record; retracted incidents are suppressed from this view.
- Is Johnson and Johnson MedTech safe?
- Johnson and Johnson MedTech has 2 active incidents on record in the DEPLOY registry. 2 incidents on record (1 minor). Most recent: Jul 2026. Retracted incidents are excluded from this count.
Methodology: Verified · 1 source (no primary) · last reviewed 2026-07-23
Verification posture
Verified
Medium confidence
Review state
Stable
Last reviewed 2026-07-23
Sources by quality tier
- 1
- secondary-established-publication
- Established publication
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Johnson and Johnson MedTech.In the press
Recent coverage mentioning Johnson and Johnson MedTech from third-party publications. Automatically surfaced; not part of the verified registry record.
Johnson and Johnson's robotic surgery device gets U.S. FDA marketing authorization
FDA grants De Novo marketing authorization to J&J's Ottava surgical robot, clearing it to compete with Intuitive Surgical's da Vinci in the soft-tissue robotic surgery market.
FDA clears J&J's Ottava surgical robot for US launch
FDA clears Johnson & Johnson's Ottava surgical robot for US launch, following de novo submission in January 2026 and successful FORTE clinical study.
Johnson & Johnson wins FDA nod for Ottava surgical robot
FDA De Novo authorization for Ottava robotic surgery system. Nearly six years from first unveiling. Competes with Intuitive da Vinci.
J&J Receives FDA Market Authorization for Ottava
FDA De Novo authorization for Ottava robotic surgical system for general surgery procedures.
Machine-readable surfaces
- Markdown mirror: /companies/johnson-johnson-medtech.md
- RSS feed: /companies/johnson-johnson-medtech/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/effe2229-340b-4d42-bbaa-5ceed51ea610
- Revision history: /companies/johnson-johnson-medtech/history
- Data documentation: /data
- Query this programmatically: Deploy MCP